Matthew Hall, in Bancroft, ID - General Practice

Matthew Hall, is a General Practice physician based in Bancroft, Idaho. Matthew Hall is licensed to practice in Idaho (license number O-1063) and his current practice location is 1232 Rigby Rd, Bancroft, Idaho. He can be reached at his office (for appointments etc.) via phone at (208) 251-3800.

NPI number for Matthew Hall is 1932581089 and his current mailing address is Po Box 119, Bancroft, Idaho. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1932581089.

Contact Information

	Matthew Hall,
	1232 Rigby Rd, Bancroft, ID 83217
	(208) 251-3800
	Not Available

Physician's Profile

Full Name	Matthew Hall
Gender	Male
Speciality	General Practice
Location	1232 Rigby Rd, Bancroft, Idaho
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1932581089
Provider Enumeration Date: 06/25/2015
Last Update Date: 06/25/2018

Medical Identifiers

Medical identifiers for Matthew Hall such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1932581089	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
208D00000X	General Practice	O-1063 (Idaho)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Matthew Hall is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Matthew Hall, Po Box 119, Bancroft, ID 83217-0119 Ph: () -	Matthew Hall, 1232 Rigby Rd, Bancroft, ID 83217 Ph: (208) 251-3800

News Archive

First intestine transplant in Michigan performed on 50-year-old Port Austin patient

The first intestine (bowel) transplant in Michigan was performed on a 50-year-old patient from Port Austin by physicians at Henry Ford Hospital.

Birmingham dermatologist first to offer anti-cellulite Cellulaze procedure

Dr. Barry Ginsburg, a Birmingham, AL based Dermatologist today announced his practice is the first in the state to offer the Cellulaze by Cynosure, the world's first and only minimally invasive medical device designed to treat women who have struggled to eliminate cellulite through diet and exercise, or have tried the myriad of lotions and creams currently on the market.

Methylphenidate improves vigilance performance of ADHD children with poor sleep

WESTCHESTER, Ill. - In the first known study of its kind, an article published in the August 1st issue of the journal SLEEP finds that children with attention deficit hyperactivity disorder (ADHD), and whose sleep efficiency is poor, experience significant improvement on some measures of the Continuous Performance Test (CPT) if they are treated with methylphenidate (MPH).

Phase 2b clinical trial data of SGLT2 inhibitor in patients with type 2 diabetes presented at ADA 2010

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that canagliflozin, an investigational, oral, selective sodium-glucose transporter-2 inhibitor, improved glycemic control, and was also associated with a decrease in body weight, in a Phase 2b dose-ranging trial in patients diagnosed with type 2 diabetes who were concurrently treated with metformin. The data were presented at the 70th American Diabetes Association Scientific Sessions.

Small coils activate neurons to modulate brain-cell activity

Magnetic fields generated by microscopic devices implanted into the brain may be able to modulate brain-cell activity and reduce symptoms of several neurological disorders.

Matthew Hall, - General Practice in Bancroft, ID